Prostate cancer screening compares favorably to screening for breast cancer in identifying significant cancers, reducing ...

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation ...

Although immunotherapy progress in prostate cancer has been slow, emerging strategies like bispecific T-cell engagers (BiTEs) show promise in overcoming historical resistance. In a recent discussion, ...

Leapman, MD, MHS, associate professor of urology at Yale University, addresses a critical and often overlooked limitation in the current landscape of prostate cancer biomarkers: while these tools have ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced ...

Circulating tumor DNA levels a few weeks after immunotherapy initiation could help identify patients with melanoma at greatest risk for recurrence or death.A retrospective analysis showed individuals ...

Prostate cancer is one of the most common cancers affecting men around the world. It develops in the prostate, a small gland ...

Increasing use of blood tests to detect prostate cancer is leading to overworked doctors. NTNU has now created an AI diagnostic tool that can help lighten the burden.

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic ...

A recent study found that men with low testosterone levels were associated with a 60 percent higher risk that prostate cancer could progress to a more aggressive state over time. Prostate cancer is ...

Drs Uzzo, Chung, and Croll of Fox Chase Cancer Center at Temple University Health discuss top presentations from the ASCO Genitourinary Cancers Symposium 2026. The American Society of Clinical ...